The short answer: breast cancer screening guidelines differ by country and by a woman’s individual risk level. For average-risk women, most international guidelines recommend starting mammography between ages 40 and 50, with screening every one to two years [3][7][13]. Women at high risk, including those with BRCA mutations or a strong family history, are advised to start earlier and may need additional imaging such as MRI [10][17]. In low- and middle-income countries, where mammography is often unavailable or unaffordable, the World Health Organization and national guidelines emphasise breast awareness, clinical breast examination, and timely diagnosis for symptomatic women as practical interim strategies [5][15].
Breast cancer screening is not a single test. It is a pathway that begins with identifying who is at risk, continues with imaging at recommended intervals, and ends with timely diagnosis and treatment when something abnormal is found. The guidelines that govern this pathway vary widely across regions, reflecting differences in resources, disease patterns, and health system capacity [6].
This article explains what the major guidelines recommend, how they differ, and what the evidence says about the benefits and limitations of screening.
What screening means for average-risk women
For women with no personal history of breast cancer, no known high-risk genetic mutation, and no strong family history, the term used is “average risk.” Guidelines for this group focus on mammography, an X-ray of the breast that can detect tumours before they can be felt [3][17].
The American Cancer Society recommends that women have the option to start annual mammograms at age 40, that women aged 45 to 54 get mammograms every year, and that women 55 and older can switch to every two years or continue yearly [3][10]. Screening should continue as long as a woman is in good health and expected to live at least 10 more years [17].
The American College of Physicians, in updated guidance published in 2026, recommends biennial mammography for women aged 50 to 74. For women aged 40 to 49, the guidance recommends shared decision-making, where the woman and her clinician discuss the benefits and harms before deciding whether to start screening [7][14].
The United Kingdom National Health Service invites women for breast screening from age 47 to 73, with screening every three years [4]. The Asian consensus recommendations advise regular mammography every two years for women aged 45 to 69, with the option to screen women aged 40 to 44 and 70 to 74 where there is emerging evidence of benefit [13].
The table below summarises the main differences.
| Guideline | Start Age | Interval | Stop Age |
|---|---|---|---|
| American Cancer Society [3] | 40 (option) | Yearly 45-54, then every 1-2 years | While in good health |
| American College of Physicians [7] | 50 (biennial) | Every 2 years | 74 |
| UK NHS [4] | 47 | Every 3 years | 73 |
| Asian Consensus [13] | 45 | Every 2 years | 69 |
Screening for high-risk women
Women with a known BRCA1 or BRCA2 mutation, a strong family history, or a history of chest radiation at a young age are considered high risk. For these women, guidelines recommend starting screening earlier and using additional imaging [10][17].
The American Cancer Society recommends that high-risk women get a breast MRI and a mammogram every year, typically starting at age 30. This applies to women with a lifetime risk of 20% to 25% or greater, those with a known BRCA mutation, those with a first-degree relative with a BRCA mutation who have not been tested themselves, and those who had chest radiation before age 30 [17].
The UK National Institute for Health and Care Excellence notes that additional pathogenic variants beyond BRCA, including PALB2, CHEK2, ATM, RAD51D, RAD51C, and BARD1, have been identified. This has implications for genetic testing thresholds and for surveillance recommendations [11].
The evidence on benefits and harms
Mammography screening has been shown to reduce breast cancer mortality. The evidence review conducted for the US Preventive Services Task Force examined randomized trials and observational studies to assess the effectiveness of different screening strategies on breast cancer morbidity and mortality [2].
But screening also carries documented harms. False-positive results are common, especially in younger women and those with dense breast tissue. Data from the Breast Cancer Surveillance Consortium show that for women aged 40 to 49, false-positive mammography rates were 121.2 per 1,000 women screened. Over 10 years, the cumulative rate of false-positive results was 61% for annual screening and 41% for biennial screening [9].
Overdiagnosis, the detection of cancers that would never have caused symptoms or death, is another concern. Combined results from two trials that provided the least biased estimates suggested overdiagnosis rates of 10.7% to 19.0% for invasive cancer plus DCIS [9].
The American College of Physicians noted that annual mammography carries a 50% to 60% chance of a false-positive result over 10 years, which can lead to unnecessary tests, psychological distress, and reduced adherence to future screening [14].
Screening in low- and middle-income countries
In many low- and middle-income countries, mammography is not widely available or affordable. A review of screening in Nigeria noted that the United Kingdom, Canada, Australia, and the United States have 21, 40, 63, and 89 mammography units per million women, respectively. Comparable data for Nigeria were unavailable, but access to diagnostic facilities is limited and poses significant barriers [5].
The WHO’s National Cancer Screening Guidelines for African countries emphasise a different approach. Rather than recommending population-wide mammography, they focus on breast awareness, clinical breast examination by trained health workers, and timely diagnosis for women with symptoms [15].
A review of breast cancer screening in Asian countries found that low-income countries lack resources for screening, while high-income countries fail to fully benefit from national programmes because of underutilisation of preventive services. The age distribution of breast cancer in Asia differs from Western populations, peaking approximately a decade earlier, most commonly affecting women aged 40 to 50 [6].
The review of screening in Nigeria concluded that until population-based screening becomes feasible, targeting symptomatic patients through rapid diagnostic pathways and subsidised treatment access may be the most effective interim strategy. This aligns with the country’s National Cancer Control Plan, which emphasises a phased approach to scaling diagnostic capacity [5].
What is myth, not documented
Myth: Breast self-exam is a recommended screening method. Research has not shown that regular breast self-examination lowers the risk of dying from breast cancer. The American Cancer Society does not recommend it as a routine screening test. Instead, it advises women to know how their breasts normally look and feel and to report any changes to a healthcare provider [3].
Myth: Clinical breast exam is part of routine screening. Studies show that clinical breast examination adds little benefit when regular mammograms are available. The American Cancer Society does not recommend it as a routine screening test for average-risk women in the United States [3].
Myth: Screening prevents all breast cancer deaths. Screening can find cancers earlier, when treatment is more likely to be successful, but it does not prevent all deaths. Some cancers are aggressive or are missed by screening. The benefits of screening must be weighed against the harms, including false positives and overdiagnosis [9][14].
Myth: Every woman needs a mammogram every year starting at 40. Guidelines vary, and the evidence supports a range of approaches. The American College of Physicians recommends biennial screening for women 50 to 74 and shared decision-making for women 40 to 49 [7]. The UK screens every three years from age 47 [4]. The best approach depends on individual risk, preferences, and the health system context.
The bottom line
Breast cancer screening guidelines vary across countries and reflect different balances of benefits and harms. For average-risk women, mammography is the main screening tool, with most guidelines recommending starting between ages 40 and 50 and screening every one to three years. High-risk women should start earlier and may need MRI in addition to mammography. In low- and middle-income countries, where mammography is often unavailable, breast awareness and clinical breast examination remain practical interim strategies. No screening method is perfect. The goal is to find cancers early enough to treat effectively while minimising the harms of false positives and overdiagnosis.
Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice. Screening recommendations depend on individual risk factors. If you have concerns about breast cancer screening, consult a qualified healthcare provider. We welcome your feedback and corrections. Please contact us if you notice any errors.
References
[1] How can self-administered cancer screening tests be implemented in screening programmes to improve access?, World Health Organization. https://iris.who.int/server/api/core/bitstreams/8945fe58-11e9-46a6-96a5-0bae359c832d/content
[2] Screening for Breast Cancer: US Preventive Services Task Force Evidence Report, JAMA. https://www.uspreventiveservicestaskforce.org/home/getfilebytoken/Pboxx4DR35wz5GPozm-XNF
[3] Breast Cancer Screening Guidelines FAQs, American Cancer Society. https://www.cancer.org/cancer/types/breast-cancer/frequently-asked-questions-about-the-american-cancer-society-new-breast-cancer-screening-guideline.html
[4] Breast screening: Scenario, NICE CKS. https://cks.nice.org.uk/topics/breast-screening/management/breast-screening/
[5] Breast Cancer Screening in Nigeria: A Review, ASCO Global Oncology. https://ascopubs.org/doi/pdf/10.1200/GO-25-00027
[6] Breast Cancer Screening in Asian Countries: Epidemiology, Screening Practices, Outcomes, Challenges, and Future Directions, Korean Journal of Radiology. https://kjronline.org/search.php?code=0068KJR&id=10.3348/kjr.2025.0338&vmode=FULL&where=aview
[7] Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement From the American College of Physicians, Annals of Internal Medicine. https://www.uptodate.com/contents/screening-for-breast-cancer-strategies-and-recommendations/abstract/46
[8] European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis, WHO. https://cci4eu-staging.aws-lcb.iarc.who.int/resource/european-guidelines-for-quality-assurance-in-breast-cancer-screening-and-diagnosis/
[9] Harms of Routine Mammography Screening, US Preventive Services Task Force. https://www.uspreventiveservicestaskforce.org/Home/GetFile/1/16475/breastcanscr-final-evidrev/pdf
[10] American Cancer Society Guidelines for the Early Detection of Cancer, American Cancer Society. https://www.cancer.org/cancer/screening/american-cancer-society-guidelines-for-the-early-detection-of-cancer.html
[11] Review protocol for carrier probability at which genetic testing should be offered, NICE. https://www.nice.org.uk/guidance/gid-ng10438/documents/review-protocols-4
[12] Recommendations for Breast Cancer Screening, BIGOSA. https://bigosa.co.za/resources-news/
[13] Asian consensus recommendations for the treatment of patients with early breast cancer, Yonsei Medical Library. https://ir.ymlib.yonsei.ac.kr/bitstream/22282913/201090/1/T202406521.pdf
[14] ACP Updates Guidance on Breast Cancer Screening for Asymptomatic, Average-Risk Women, Beth Israel Deaconess Medical Center. https://research.bidmc.org/mara-schonberg/news/acp-updates-guidance-breast-cancer-screening-asymptomatic-average-risk-women
[15] National Cancer Screening and Early Diagnosis Guidelines, WHO Regional Office for Africa. https://www.afro.who.int/sites/default/files/2025-03/National%20Cancer%20Screening%20Guidelines%202024.pdf
[16] Breast Cancer Screening, US Preventive Services Task Force. https://www.uspreventiveservicestaskforce.org/uspstf/search_results?searchterm=breast%20cancer
[17] American Cancer Society Recommendations for the Early Detection of Breast Cancer, American Cancer Society. https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html
[18] Early and locally advanced breast cancer: diagnosis and management, NICE. https://www.nice.org.uk/guidance/ng101/evidence/june-2026-exceptional-surveillance-of-early-and-locally-advanced-breast-cancer-diagnosis-and-15728073229
[19] National Guideline for breast health, early diagnosis and timely breast cancer management in Ethiopia, NCCP-UICC. https://nccp-uicc.org/resources/national-guideline-breast-health-early-diagnosis-and-timely-breast-cancer-management-0
[20] Breast Cancer Screening in Asian Countries, Korean Journal of Radiology. https://kjronline.org/search.php?code=0068KJR&id=10.3348/kjr.2025.0338&vmode=FULL&where=aview
